AML
News
FDA approves ivosidenib frontline for certain AML patients
The expanded approval means that ivosidenib can be used first-line for acute myeloid leukemia patients with an IDH1 mutation who are not eligible...
Conference Coverage
Study highlights lack of data on transgender leukemia patients
NEWPORT BEACH, CALIF. – Researchers identified transgender leukemia patients by detecting gender-karyotype mismatches.
Video
ALF 2019 showcases evolving treatment of AML
NEWPORT BEACH, CALIF. – Dr. Martin Tallman discusses meeting presentations on the treatment of AML.
Video
Gilteritinib prolonged survival in FLT3-mutated AML
Patients with acute myeloid leukemia and FLT3-activating mutations are at increased risk for early relapse and poor overall survival.
Conference Coverage
Anti-CD45 conditioning looks safe, feasible in relapsed AML
HOUSTON – Iomab-B use has resulted in successful engraftment for all patients who have received it and gone on to transplant, despite active...
Conference Coverage
In IDH-mutated AML, first-line IDH inhibitors plus chemo may boost remission
SAN DIEGO – Minimal residual disease and mutational clearance were seen in a significant proportion of patients.
Video
Model bests IPSS-R for predicting survival, risk for AML in myelodysplastic syndrome
Video
Beat AML trial delivers genomic results in 7 days
SAN DIEGO – The umbrella trial, sponsored by the Leukemia & Lymphoma Society, harnesses technology to speed genomic results that could...
News
Azacitidine-nivolumab combo 'encouraging' in AML
The response rate was higher among patients who had not received prior treatment with hypomethylating agents.
Conference Coverage
Five “can’t miss” oncologic emergencies
All patients with suspected leukemias should be admitted.
